This Article  • Full text  • PDF  • VIDEO SUPPLEMENT  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pain  • Dermatologic Procedures  • Dermatologic Procedures, Other  • Facial Plastic Surgery  • Cosmetic Surgery/ Procedures  • Alert me on articles by topic  Social Bookmarking   What's this?

Thomas Lewis, MD; Gordon Jacobsen, MS; David Ozog, MD

Arch Dermatol. 2008;144(12):1657-1658.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Botulinum toxin type A (Botox; Allergan Inc, Irvine, California) injection for facial enhancement is the most common cosmetic procedure performed in the United States.^1-3 Patient comfort and pain control is important for patient satisfaction and for patient retention after the cosmetic procedure. The use of preservative-containing isotonic sodium chloride solution (normal saline), topical anesthesia, and cryoanalgesia prior to injection of botulinum toxin type A or B decreases patient discomfort, as does the use of 32-gauge rather than 30-gauge needles.^4-6 Since intrafollicular orifice injection (IFOI) decreases the pain of local anesthesia,⁷ we extend the technique to the injection of botulinum toxin into the glabellar region. In the present study, we compared the IFOI technique with nonfollicular traditional injection (TI) with regard to patient pain perception.

Methods

This prospective, randomized study was limited to female patients with no history of receiving Botox. Exclusion criteria . . . [Full Text of this Article]

Results

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?